Clinical characteristics
| Control subjects in lung tissue studies (n=21) | Control subjects in plasma studies (n=30) | IPF patients in lung tissue studies (n=17) | IPF patients in plasma studies (n=36) | |
|---|---|---|---|---|
| Age (years) | 66 (53–78) | 67 (48–75) | 64 (56–75) | 63(55–72) |
| Sex (M/F) | 15/6 | 20/10 | 12/5 | 25/11 |
| Smoking | ||||
| Never smoked/smokers | 9/12 | 8/22 | 5/12 | 6/30 |
| Pack-years | 26 (0–32) | 24 (0–29) | 27.5 (0–32) | 30 (0–38) |
| FEV1, pred | 95.2 (90–104) | 96 (93–105) | 73.7 (58–103) | 72 (50–102) |
| FVC, % pred | 96 (93–106) | 98.4 (94–105) | 72.2 (63–98) | 74 (48–92) |
| TLC, % pred | 95 (92–105) | 96 (91–107) | 73.5 (45–89) | 66 (43–90) |
| Tlco, % pred | 94.2 (91–107) | 97 (92–107) | 50.4 (32–61) | 40.5 (20–63) |
| Ground glass % | 0 | ND | 15 (5–40) | 10 (5–30) |
| Honeycombing % | 0 | ND | 28 (10–40) | 25 (12–35) |
| Pao2, mm Hg | 94 (84–100) | 96 (85–100) | 65 (45–88) | 60 (40–85) |
| mPAP mm Hg/L/min | ND | ND | 38.5 (34–44) | 43 (36–48) |
| Steroid (y/n) | 0/21 | 0/30 | 1/15 | 12/15 |
| Azathioprine (y/n) | 0/21 | 0/30 | 4/17 | 6/36 |
| NAC (y/n) | 0/21 | 0/30 | 14/17 | 28/36 |
| Pirfenidone (y/n) | 0/21 | 0/30 | 4/17 | 8/36 |
Data are shown as median (IQR).
Steroid/azathioprine/pirfenidone refers to patients who received this treatment at the time of pulmonary biopsy.
% pred, % predicted; Tlco, transfer factor of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ground glass %, percentage of pulmonary parenchyma with ground glass in CT image; honeycombing %, percentage of pulmonary parenchyma with honeycombing in CT image; IPF, idiopathic pulmonary fibrosis; mPAP, mean pulmonary artery pressure; NAC, N-acetyl-ι-cysteine; ND, not determined; pack-year, 1 year of smoking 20 cigarettes per day; Pao2, oxygen tension in arterial blood; TLC, total lung capacity.